The Business Of Biotech Podcast
-
Engineering B Cells With Immusoft's Sean Ainsworth
12/5/2025
On this week's episode of the Business of Biotech, Sean Ainsworth, CEO and Chairman at Immusoft, talks about transitioning from the research bench to entrepreneurship, his M&A experiences as a biotech founder, and why engineered B cell therapies offer a better, more patient-friendly administration for lysosomal storage diseases currently treated with enzyme replacement therapies.
-
Building A Cancer Pipeline In A Molecule With Actuate Therapeutics' Dan Schmitt
11/26/2025
On this week's episode of the Business of Biotech, Dan Schmitt, President and CEO at Actuate Therapeutics, talks about building a company around elraglusib, a GSK-3β inhibitor for cancer.
-
Biotech Collaboration Strategy With IGI's Cyril Konto, M.D.
11/20/2025
On this week's Business Of Biotech episode, Cyril Konto, M.D., president, executive director, and CEO at Ichnos Glenmark Innovation (IGI) talks about the promise of multi-specific antibodies, funding the company during the 'biotech winter,' closing a $700 million upfront licensing deal with AbbVie, the impact of China's rising biotech sector, and the keys to successful collaboration.
-
Biotech Funding And IPO Temperature Check With CREATE Medicine's Allan Shaw
11/13/2025
Allan Shaw, Chief Financial Officer and Chief Business Officer at CREATE Medicines, is back on the Business of Biotech this week, with a temperature check on biotech funding and the IPO market.
-
Funding Tips And Moving From R&D To Commercial With Madrigal Pharmaceuticals' Mardi Dier
11/5/2025
On this week's episode of the Business of Biotech, Mardi Dier, CFO at Madrigal Pharmaceuticals, talks about building relationships in investment banking and investor relations before moving into business development and becoming a chief financial officer.
-
Emerging From Stealth With Vima Therapeutics' Bernard Ravina, M.D.
10/31/2025
On this week's episode of the Business of Biotech, we're speaking with Bernard Ravina, M.D., CEO at Vima Therapeutics, a company that emerged from stealth in May with $60 million Series A financing to develop an oral candidate for dystonia, a movement disorder.
-
BoB in South Florida: Rich Daly, Catalyst Pharmaceuticals
10/24/2025
On this week's episode — the last of our four-part series focused on South Florida — we catch up with Rich Daly, CEO at Catalyst Pharmaceuticals, a member of Life Science Leader's editorial advisory board and Miami-based location host for our in-person series.
-
BoB In South Florida: Anthony Japour, M.D., iTolerance
10/16/2025
On this week's episode of the Business of Biotech, Anthony Japour, M.D., CEO at iTolerance, talks about his work as a physician treating infectious diseases, his CEO role in diagnostics at the height of the COVID-19 pandemic, what he learned working as a medical director at a large CRO, and iTolerance's work toward a cure for Type 1 diabetes that doesn't require chronic immunosuppression.
-
BoB In South Florida: Daniel Teper, NAYA Therapeutics
10/9/2025
In this week's episode of the Business of Biotech -- part two in a four-part series recorded in-person at Catalyst Pharmaceuticals' Miami headquarters -- we're speaking with Daniel Teper, an entrepreneur and most recently, founder and CEO at NAYA Therapeutics.
-
BoB In South Florida: Raquel Cabo, Miami Biotech Collective
10/2/2025
The Business of Biotech is on location in Miami this week! For the first episode in this four-part series on the biotech scene in South Florida, Raquel Cabo, Founder and President of the Miami Biotech Collective, talks about her experiences as a member of the founding team at Ovid Therapeutics, why South Florida needed an organization to connect regional drug developers, and more.